首页|间充质干细胞治疗新型冠状病毒肺炎的机制及研究进展

间充质干细胞治疗新型冠状病毒肺炎的机制及研究进展

扫码查看
新型冠状病毒肺炎(COVID-19)感染性强,且重型及危重型患者病死率高,缺乏特异性治疗方法,急需寻找安全有效的治疗方法.间充质干细胞(MSCs)具有免疫调节、组织修复、再生、迁移和归巢、抗病毒和抗炎等生物学特性.目前应用MSCs治疗COVID-19的研究已逐步开展.本文就2019新型冠状病毒(2019-nCoV)的致病机制、MSCs治疗COVID-19的潜在机制及面临的挑战进行综述.
Mechanism and research progress of mesenchymal stem cells in treatment of COVID-19
Coronavirus disease 2019(COVID-19)is highly infectious,severe and critically ill patients have high mortality and lack specific treatment,so it is urgent to find safe and effective treatment methods.Mesenchymal stem cells(MSCs)have biologi-cal properties such as immune regulation,tissue repair,regeneration,migration and homing,antiviral and anti-inflammatory.At present,studies on use of MSCs in treatment of COVID-19 have been gradually carried out.This paper reviews pathogenesis of 2019 novel coronavirus(2019-nCoV),potential regulatory mechanisms and challenges of MSCs in treatment of COVID-19.

Mesenchymal stem cellsCOVID-19Clinical trials

凌小穗、何海萍、李凡、张丽华

展开 >

昆明理工大学医学院,昆明 650500

华东师范大学附属芜湖医院,芜湖 241060

间充质干细胞 新型冠状病毒肺炎 临床试验

国家自然科学基金地区科学基金云南省医学学科带头人项目芜湖市科技计划

81760028D-20180172022jc75

2024

中国免疫学杂志
中国免疫学会,吉林省医学期刊社

中国免疫学杂志

CSTPCD北大核心
影响因子:0.926
ISSN:1000-484X
年,卷(期):2024.40(1)
  • 2